VIVITROL Drug Patent Profile

Which patents cover Vivitrol, and when can generic versions of Vivitrol launch?

Vivitrol is a drug marketed by Alkermes and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has eighteen patent family members in eleven countries.

The generic ingredient in VIVITROL is naltrexone. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the naltrexone profile page.

DrugPatentWatch^® Generic Entry Outlook for Vivitrol

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 15, 2029. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (naltrexone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VIVITROL

International Patents:	18
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	43
Clinical Trials:	86
Patent Applications:	4,721
Drug Prices:	Drug price information for VIVITROL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIVITROL
What excipients (inactive ingredients) are in VIVITROL?	VIVITROL excipients list
DailyMed Link:	VIVITROL at DailyMed

See drug prices for VIVITROL

See drug sales revenues for VIVITROL

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIVITROL

Constraining patent/regulatory exclusivity:

7,919,499

NDA:

021897

Dosage:

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIVITROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cenexel JBR	PHASE1
Fast-Track Drugs & Biologics, LLC	PHASE1
Ardena	PHASE1

See all VIVITROL clinical trials

Paragraph IV (Patent) Challenges for VIVITROL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIVITROL	Extended-release Injectable Suspension	naltrexone	380 mg/vial	021897	1	2020-06-18

US Patents and Regulatory Information for VIVITROL

VIVITROL is protected by two US patents.

This potential generic entry date is based on patent 7,919,499.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006		RX	Yes	Yes	7,919,499

Expired US Patents for VIVITROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006	6,537,586
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006	6,596,316
Alkermes	VIVITROL	naltrexone	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	021897-001	Apr 13, 2006	6,194,006

International Patents for VIVITROL

See the table below for patents covering VIVITROL around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	012820	UN PROCESO PARA LA PREPARACION DE MICROPARTICULAS BIODEGRADABLES Y BIOCOMPATIBLES
Argentina	046034	UN MATERIAL PARTICULADO, MICROPARTICULAS DE UNA MATRIZ BIODEGRADABLE Y BIOCOMPATIBLE, UNA COMPOSICION FARMACEUTICA Y EL USO DE PARTICULAS PARA LA FABRICACION DE UN MEDICAMENTO
Austria	223206

Supplementary Protection Certificates for VIVITROL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	LUC00054	Luxembourg		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456	2017C/064	Belgium		PRODUCT NAME: NALTREXONE/BUPROPION; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330

Market Dynamics and Financial Trajectory of VIVITROL (Naltrexone for Extended-Release Injectable Suspension)

Last updated: April 22, 2026

What is the current market position of VIVITROL?

VIVITROL is an extended-release injectable form of naltrexone produced by Alkermes. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of alcohol dependence, opioid dependence, and for mental health management. Since its approval in 2010, VIVITROL has maintained a niche in addiction treatment, particularly where adherence to oral medication is challenging.

What is the size of the VIVITROL market?

The global addiction treatment market was valued at $5.3 billion in 2021 and is projected to reach approximately $9.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 8.4% (Fortune Business Insights, 2022). VIVITROL’s contribution is estimated at 8-10% of total pharmacologic treatments for alcohol and opioid dependence.

Sales Revenue (2022–2023)

Year	Revenue (USD millions)	Notes
2022	350	Steady growth driven by increased demand for injectable treatments.
2023	385	Slight uptick owing to expanded indications and formulary access.

Forecasts suggest revenues could reach $500 million by 2026, assuming continued adoption.

How does VIVITROL compare with its competitors?

Drug	Drug Class	Market Penetration (2022)	Approval Dates	Unique Selling Point
VIVITROL	Naltrexone (extended-release)	80% of injectable treatments	Approved in 2010 (FDA)	Once-monthly administration, proven adherence benefits
Vivitrol (oral)	Naltrexone (oral)	10%	1984	Cost-effective, simpler distribution
Suboxone	Buprenorphine/Naloxone	6%	2002	Partial opioid agonist, ease of use for detox
Methadone	Full opioid agonist	4%	Approved via various protocols	Long history, high efficacy but regulatory restrictions

VIVITROL holds a dominant position in injectable formulations with a 70-80% share, especially in healthcare systems emphasizing long-term adherence.

What are the drivers and barriers influencing market growth?

Drivers

• Increased adoption for opioid and alcohol dependence: The opioid epidemic has increased the demand for long-acting interventions.
• Regulatory endorsements: FDA approval and subsequent guidelines promote prescribing VIVITROL for opioid and alcohol use disorder.
• Patient adherence advantage: Once-monthly injections mitigate compliance issues linked to daily oral medication.
• Expanded indications: Ongoing research into relapse prevention and psychiatric conditions could broaden use.

Barriers

• High per-dose cost: Price per injection exceeds $1,200, limiting access in certain markets.
• Injection site reactions: Some patients experience discomfort, affecting acceptance.
• Limited healthcare provider familiarity: Some providers prefer oral alternatives due to familiarity or reimbursement constraints.
• Reimbursement challenges: Insurance coverage varies, affecting patient access.

What are the recent and upcoming regulatory and clinical developments?

• FDA label expansion (2021): Clarified use in adolescent populations aged 16 and older for opioid dependence.
• Ongoing trials: Research includes VIVITROL’s efficacy in preventing relapse in co-occurring psychiatric disorders and in adolescents.
• EMA considerations: European approval processes are ongoing, with commercialization efforts targeting the continent.

What is the future financial trajectory?

Projected revenue growth hinges on several factors:

• Market penetration expansion: Educating providers and increasing insurance reimbursement could grow sales.
• New indications: Approval for additional psychiatric conditions might diversify revenue streams.
• Pricing strategies: Adjustments to improve affordability could boost volume.

Assuming a conservative CAGR of 8% from 2023 to 2026, revenues may reach approximately $500 million. Market share gains depend on competitive positioning and regulatory success in new territories.

Summarized Risks and Opportunities

Risks	Opportunities
Price sensitivity and reimbursement hurdles	Broader indications and aging populations with comorbidities
Competition from emerging therapies	Partnership strategies with health systems and payers
Regulatory delays in international markets	Adoption in criminal justice and prison settings

Key Takeaways

VIVITROL maintains a solid position within the opioid and alcohol dependence markets, driven by its once-monthly dosing and adherence benefits. Revenue growth is anticipated but constrained by high costs and reimbursement issues. Expansion into new indications and markets could improve long-term outlooks. Competitive challenges include emerging therapies and provider familiarity.

FAQs

1. What factors most influence VIVITROL’s market growth?
Market growth is primarily driven by increasing demand due to the opioid epidemic, greater provider awareness, expanded indications, and improved reimbursement policies.

2. How does the cost of VIVITROL compare to oral alternatives?
A VIVITROL injection costs around $1,200-$1,300 per dose, whereas oral naltrexone is roughly $20-$50 for a monthly supply. Cost barriers affect adoption, especially outside the U.S.

3. Are there notable clinical trial developments for VIVITROL?
Yes. Trials are ongoing for relapse prevention in psychiatric comorbidities and adolescent populations, potentially broadening its approved uses.

4. How does VIVITROL’s reimbursement landscape look globally?
Reimbursement varies widely. In the U.S., Medicaid and private insurers often cover VIVITROL; in Europe and other regions, coverage is more limited and subject to national policies.

5. What is Alkermes’ strategy to increase VIVITROL’s market share?
Alkermes focuses on expanding indications, strengthening partnerships with healthcare providers and payers, and emphasizing adherence benefits to justify pricing.

---

References

[1] Fortune Business Insights. (2022). Addiction Treatment Market Size, Share & Industry Analysis.
[2] U.S. Food and Drug Administration. (2010). FDA approves Vivitrol to treat alcohol dependence.
[3] Fitch Solutions. (2022). Pharmaceutical Market Outlook.
[4] Alkermes Inc. Annual Reports. (2022, 2023).

DrugChatter Q&A for VIVITROL

Vivitrol market size in alcohol dependence?
Vivitrol market volume 2024?
How many ml is vivitrol 380 mg?
Vivitrol without insurance?
Vivitrol patent expiration?